Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
2019 · Signal Transduction and Targeted Therapy · 1,045 citations
https://doi.org/10.1038/s41392-019-0095-0
X
Xiawei Wei
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
253
Papers
21.1K
Citations
66
h-index
179
i10-index
Xiawei Wei is an academic researcher from Huawei Technologies (China). The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & Immunotherapy and Immune Responses & Immune cells in cancer. The author has an h-index of 66, co-authored 216 publications.
ORCID: 0000-0002-6513-6422Papers by this author
worksThe molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
2022 · Journal of Hematology & Oncology · 888 citations
https://doi.org/10.1186/s13045-022-01347-8
A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome
2021 · Signal Transduction and Targeted Therapy · 632 citations
https://doi.org/10.1038/s41392-020-00451-w
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
2022 · Journal of Hematology & Oncology · 544 citations
https://doi.org/10.1186/s13045-022-01282-8
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
2019 · Molecular Cancer · 494 citations
https://doi.org/10.1186/s12943-019-1090-3
Cellular Toxicity and Immunological Effects of Carbon-based Nanomaterials
2019 · Particle and Fibre Toxicology · 464 citations
https://doi.org/10.1186/s12989-019-0299-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat